Crescendo Bioscience announced this month that it had finally raised $28 million from investors that would be used towards developing and commercializing blood tests that can detect disease activity in patients suffering from rheumatoid arthritis and other auto-immune diseases.
Residents in Oregon, who are currently suffering from the debilitating chronic disease RA, were probably excited by the company’s announcement because they know what this could mean for scientists in the future. Approximately 1.5 million Americans are currently suffering from this medical disability, many of whom may be over the age of 50; but with the help of this test, earlier detection could allow scientists to develop better treatment programs.
Crescendo Bioscience is currently working with collaborators from many leading medical institutions to improve their understanding of the biology of RA and how it affects patients. With their new funding, the company has expanded their field sales organization which has allowed them to expand their customer base to nearly 500 rheumatologists thereby increasing their sample group to more than 30,000 patients.
“Patients suffering from RA are treated by a concentrated group of only 3,500 rheumatologists who rely on a number of subjective measures to assess disease activity and response to treatment, which may lead to suboptimal outcomes. Vectra DA’s ability to provide an objective assessment addresses this opportunity head on,” explains the managing director for Life Sciences at Safeguard.
According to Crescendo Bioscience, the multi-biomarker blood test known as Vectra DA will not only be able to detect the disease activity of RA, it will also be able to measure 12 other diseases that can affect the immune system, bones and other systems in the body. The amount of information gathered using this new test could give scientists the information they need to better understand how diseases work overall.
Source: The PE Hub, “Crescendo Bioscience Closes on $28M,” PE Hub Staff, Jan. 3, 2013